The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
For the treatment of adult and pediatric patients ≥ 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options
Endocrine Tumours
Thyroid Cancer
BRAF V600E
BRF117019
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Dab/Tram (dabrafenib and trametinib)
-
Single arm (Phase II)
For the treatment of adult and pediatric patients ≥ 6 years of age with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options
Gastrointestinal Cancers
Biliary tract cancer
BRAF V600E
ROAR
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Durvalumab
Gemcitabine and cisplatin
Placebo + gemcitabine and cisplatin
In combination with gemcitabine and cisplatin is indicated for the first‑line treatment of adults with unresectable or metastatic biliary tract cancer (BTC).
Gastrointestinal Cancers
Biliary tract cancer
-
TOPAZ-1
4
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
2
Trastuzumab deruxtecan
-
Pysician's ChT choice (eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel)
Montherapy for the treatment of adult patients with unresectable or metastatic HER2‑low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy
Breast Cancer
Breast Cancer
HER2-low
DESTINY-Breast04
4
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
2
Darolutamide
ADT ((androgen deprivation therapy) + docetaxel
ADT + Docetaxel + placebo
For adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy
Genitourinary Cancers
Prostate cancer
-
ARASENS
4
PRELIMINARY SCORE
OS
5
ADJUSTMENTS
FINAL SCORE
F1
2
Camrelizumab
Gemcitabine + cisplatin
Placebo + gemcitabine + cisplatin
First-line treatment of recurrent or metastatic nasopharyngeal carcinoma
Head and neck cancer
Nasopharyngeal carcinoma
-
CAPTAIN-1st
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Toripalimab
Gemcitabine + cisplatin
Placebo + gemcitabine + cisplatin
First-line treatment of recurrent or metastatic nasopharyngeal carcinoma
Head and neck cancer
Nasopharyngeal carcinoma
-
JS001-015-III-NPC
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Atezolizumab
-
Single arm (Phase II)
Patients with locally advanced or metastatic UC who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥5%
Genitourinary Cancers
Urothelial Carcinoma
PD-L1 expression ≥5%
IMvigor210 – Cohort 1
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Pembrolizumab
-
Single arm (Phase II)
Patients with locally advanced or metastatic UC who are not eligible for any platinum-containing ChT
Genitourinary Cancers
Urothelial Carcinoma
-
MK-03475-052 KEYNOTE-052
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Selpercatinib
-
Single arm (Phase I/II)
Treatment for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options (other than non-small cell lung cancer and thyroid cancer).
RET fusion-positive tumours
-
-
LIBRETTO-001
3
PRELIMINARY SCORE
OS
6
ADJUSTMENTS
FINAL SCORE
F1
3
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Treatment Setting
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
esmo.mcbs.table.heading.visualisation
esmo.mcbs.table.heading.visualisation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.